Showing 151-160 of 4925 results for "".
Quantel Derma LEDA Diode Laser System - Hair Removal at the Speed of Light
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/quantel-derma-leda-diode-laser-system-hair-removal-at-the-speed-of-light/19447/LEDA is the expandable platform system for permanent hair removal at the speed of light. LEDA applies photodynamic therapy (PDT) for the treatment of acne, Psoriasis, Vitiligo & atopic dermatitis, and for gentle skin rejuvenation. The diode laser system LEDA EPI, for hair removal, has a large spSuccessful Management of Rosacea with Lasers
https://practicaldermatology.com/topics/general-topics/successful-management-of-rosacea-with-lasers/22037/Specialists share insights to help dermatologists and patients get the most from laser therapy for rosacea.Pearls for the Diagnosis and Management of Eyelid and Lip Dermatitis
https://practicaldermatology.com/topics/general-topics/PD1009_06-php/20366/With sensitivity to diagnostic clues and initiation of appropriate therapeutic strategies, clinicians can eliminate irritant dermatitis of the lips and eyelids.On Mentorship, Open- Mindedness, and Fulfillment: A Chat with Dr. Peter Lio
https://practicaldermatology.com/youngmd-connect/wrap-ups/on-mentorship-open-mindedness-and-fulfillment-a-chat-with-dr-peter-lio/29892/Young MD Connect recently hosted a mentorship session with Dr. Peter Lio to learn from a practicing professional in the field of dermatology in a relaxed “Ask Me Anything” setting. Dr. Lio is a clinical assistant professor of dermatology and pediatrics at Northwestern University and the founding dirThe Landscape of Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/the-landscape-of-vitiligo-treatment/24467/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Lawrence Green, MD, a dermatologist practicing in Rockville, MD, about the landscape of treatments for patients with vitiligo and new therapies that may be coming from ongoing clinical trials.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.DermWireTV: Zilxi Launch, Eczema Awareness, Uninsurance Rates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-zilxi-launch-eczema-awareness-uninsurance-rates/19863/For eczema awareness month, the National Eczema Association (NEA) is offering virtual educational programs, community engagement activities, and additional free resources. Georgia, Oklahoma, and Texas have the highest rates of uninsurance. Zilxi minocycline topical foam launches as new data fromDermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisSkin Cancer Awareness, Epiduo Data, Impoyz Launch
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-skin-cancer-awareness-epiduo-data-impoyz-launch/18307/Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations